-
DiD (DiDC 18 (5)) for Cell Tracking
2026-09-30
DiD (DiDC 18 (5)) provides red, lipophilic plasma membrane labeling for cell migration tracking, neuronal tracing, and high-autofluorescence tissue imaging. This workflow-focused guide shows how to pair membrane tracking with the mitochondrial inflammation framework reported in diabetic periodontitis research—without confusing an assay aid with a therapeutic mechanism.
-
Neuromedin S (rat): Practical Protocol & QC
2026-09-30
Neuromedin S (rat), SKU B5466, provides a defined rat peptide input for controlled neuromedin U receptor signaling and GPCR/G protein signaling workflows. This guide covers preparation, handling, assay setup, and QC while emphasizing that the available dossier does not establish potency, in vivo outcomes, diagnostic utility, or therapeutic use.
-
KR-12 Antimicrobial Peptides: Design and Applications
2026-09-29
The review by Narayana and colleagues presents KR-12 as the minimal antibacterial fragment of human LL-37 and maps how sequence engineering, formulation, and biomaterial conjugation expand its utility. Its central implication is that a compact KR-12 scaffold can combine membrane-directed antimicrobial activity with anti-biofilm, endotoxin-neutralizing, and immune-regulatory functions, although translation remains constrained by assay heterogeneity and delivery challenges.
-
Naftifine HCl Research Workflows
2026-09-29
Naftifine HCl enables controlled investigation of fungal sterol disruption across susceptibility, membrane-integrity, and formulation-oriented assays. This guide pairs practical handling conditions with a careful comparison to WNT5a/GSK3/β-catenin research, clarifying where the compound is useful and where cross-domain conclusions remain untested.
-
CAF–ANGPTL4–IQGAP1 Drives Prostate Cancer Resistance
2026-09-28
A 2025 study links cancer-associated fibroblast secretion of ANGPTL4 to IQGAP1-dependent signaling, increased mitochondrial metabolism, and reduced chemotherapy sensitivity in prostate cancer. Its combination of secretome profiling, metabolic analysis, and protein-interaction assays offers a mechanistic framework for studying tumor–stroma signaling, while the reported inhibitor findings remain preclinical.
-
Resiniferatoxin (RTX): TRPV1 Pain Research Guide
2026-09-27
Resiniferatoxin (RTX) offers a route-specific way to probe—and, under carefully controlled conditions, silence—TRPV1-positive sensory afferents. This guide connects calcium-imaging workflows with pain-model selection, interpretation of the initial agonist response, and practical steps to reduce variability.
-
SEMA3E Drives Beige Fat Thermogenesis via β-Catenin
2026-09-26
A mouse study identifies SEMA3E as a regulator of beige adipocyte differentiation and thermogenic capacity in inguinal white fat, linking its effects to β-catenin signaling and mitochondrial respiration. The results suggest a candidate pathway for metabolic disorder research, while leaving open whether the mechanism applies to other adipose depots or humans.
-
BH3 Mimetics Target Senescent Breast Cancer Cells
2026-09-26
A 2020 study found that some chemotherapy-treated, TP53 wild-type breast cancer cells become vulnerable to BH3 mimetics after entering senescence. In cell and mouse models, targeting their dependence on BCL-XL, alone or with MCL1 inhibition, promoted apoptosis and improved tumor control, suggesting a strategy for addressing residual disease.
-
Dacomitinib and the Boundaries of Ferroptosis Research
2026-09-25
Dacomitinib (PF-00299804) offers a way to probe durable pan-HER signaling blockade, but its relationship to mitochondrial ferroptosis biology remains an open question. This article connects receptor-level experiments with METTL17 findings in colorectal cancer while distinguishing established evidence from testable translational hypotheses.
-
OSMI-1: O-GlcNAc Transferase Inhibitor Guide
2026-09-25
OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor for experimental control of protein O-GlcNAc modification. Its biochemical and cell-assay benchmarks support O-GlcNAcylation research, but the preeclampsia study’s protective findings from increased O-GlcNAcylation do not establish OSMI-1 as a therapeutic approach.
-
MTT Assays in Translational Cancer Research
2026-09-24
Learn how MTT connects cellular metabolic activity to drug-response phenotypes, and how to interpret that signal responsibly in translational cancer research. Using cisplatin-resistant ovarian cancer as a case study, this article outlines experimental design, complementary readouts, and practical considerations for MTT workflows.
-
Nicotinamide Riboside Chloride in iPSC-RGC Assays
2026-09-24
Pair the reproducible iPSC-to-retinal ganglion cell workflow with a carefully controlled NIAGEN intervention to ask whether NAD+ availability affects retinal-cell metabolism or assay resilience. The differentiation study establishes a strong cellular platform; adding Nicotinamide Riboside Chloride is an exploratory experimental extension, not a result demonstrated in that paper.
-
Triiodothyronine (T3) in Adipose Thermogenesis
2026-09-23
Use Triiodothyronine (T3) as a controlled endocrine perturbation alongside SETD7 knockdown, cold, or β3-adrenergic stimulation to separate thyroid receptor effects from adipose browning mechanisms. This workflow combines formulation guidance, factorial assay design, and troubleshooting for reproducible metabolic disorder research.
-
Reactive Oxygen Species Assay Kit Workflow
2026-09-22
Build a controlled live-cell oxidative stress workflow with DCFH-DA, a Rosup positive control, and practical normalization strategies. Translate ROS measurements into mechanistic studies of PM2.5 injury, Nrf2 signaling, apoptosis, and treatment response.
-
AZD2461: Reliable PARP Inhibitor Assay Design
2026-09-22
A scenario-driven guide to using AZD2461 (SKU A4164) in cell viability, proliferation, and cytotoxicity workflows. It explains assay interpretation, concentration selection, formulation, vendor evaluation, and resistance-focused breast cancer research with links to the product dossier and supporting literature.